Article
Ribometrix in potential $1B-plus Roche deal as more enter RNA fold
Rating:
0.0
Views:
180
Likes:
1
Library:
1
Pointing to his company's work on “the next frontier in small molecules,” Ribometrix Inc. CEO Mike Solomon said the potential $1 billion-plus deal with Roche Holding AG offers evidence of big pharma's mounting interest.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value